1. Борисова Т.А. Роль таксотера в лечении больных диссеминированным раком молочной железы. Материалы IV Российского национального конгресса «Человек и лекарство». М., 1998.
2. Возный Э.К. Терапия метастатического рака молочной железы. Доцетаксел. Материалы XII Российского онкологического конгресса. М., 2008.
3. Горбунова В.А. Значение таксанов в лечении рака молочной железы. Вопр. онкол. 2004; 50 (4): 492–500.
4. Давиденко И.С. Применение комбинации препаратов таксотер и доксорубицин в терапии первой линии больных первично-диссеминированным и метастатическим раком молочной железы. Автореф. дис. ... канд. мед. наук. М., 2001.
5. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ. Вестн. РОНЦ им. Н.Н.Блохина РАМН. 2008; 19 (2): 11.
6. Клиническая фармакология по Гудману и Гилману. М., 2006.
7. Baur M, van Oosterom AT, Dieras V et al. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2008; 134 (2): 125–35.
8. Bonneterre J, Dieras V, Tubiana-Hulin M et al. Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 91: 1466–71.
9. Bontenbal M, Creemers GJ, Braun HJ et al. Dutch Community Setting Trial for the Clinical Trial Group. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005; 23 (28): 7081–8.
10. Bullock К, Blackwell К. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 2008; 13 (5): 515–25.
11. Burstein HJ, Manola J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. JCO 2000; 18: 1212–9.
12. Campora E, Colloca G, Ratti R et al. Docetaxel for metastatic breast cancer: two consecutive phase II trials. Anticancer Res 2008; 28 (6B): 3993–5.
13. Chan S, Friedrichs K, Noel D et al. Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer. JCO 1999; 17: 2341–54.
14. Ciardiello F, Troiani T, Caputo F et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006; 94 (11): 1604–9.
15. Esteva FJ, Valero V, Booser D et al. Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer J Clin Oncol 2002; 20: 1800–8.
16. Gamucci T, D'Ottavio AM, Magnolfi E et al. Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 2007; 97 (8): 1040–5.
17. Jones SE, Erban J, Overmoyer B et al. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer J Clin Oncol 2005; 23, 24: 5542–51.
18. Li SF, Wang X et al. Docetaxel and capecitabine combination chemotherapy for patients with anthracycline-resistant metastatic breast cancer. Zhonghua Zhong Liu Za Zhi 2008; 30 (12): 944–6.
19. Lin YC, Chang HK et al. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer. Anticancer Drugs 2007; 18 (10): 1213–9.
20. Liu ZF, Zhang XQ et al. Low dose-intensity docetaxel monotherapy for patients with anthracycline-resistant metastatic breast cancer in poor physical status. Zhonghua Zhong Liu Za Zhi 2008; 30 (4): 317–9.
21. Malinovszky K, Johnston S, Barrett-Lee P et al. TEXAS (Taxotere Experience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemother Pharmacol 2007; 59 (3): 413–8.
22. Marty M, Cognety F et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group J Clin Oncol 2005; 23: 4265–74.
23. Mavroudis D, Alexopoulos A et al. Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin. Oncology 2003; 64: 207–12.
24. Michalaki V, Gennatas S, Gennatas K. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anticancer Drugs, 2009.
25. Miles D, Chan A, Romieu G et al Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 26: 2008, May 20 suppl; abstr LBA1011.
26. Nabholtz JM, Falkson C, Campos D et al. TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21 (6): 968–75.
27. Palmeri L, Vaglica M, Palmeri S. Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manag 2008; 4 (5): 1047–59.
28. Pegram M, Forbes J, Pienkowski T et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). ASCO 2007, LBA1008.
29. Rivera E, Mejia JA, Arun BK et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112 (7): 1455–61.
30. Robert N, Leyland-Jones B, Asmar L et al. Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer. JCO 2006; 24, 19: 2786–92.
31. Sato N, Sano M, Tabei T et al. Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer 2006; 13 (2): 166–71.
32. Schmid P, Krocker J, Kreienberg R et al. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemother Pharmacol, 2008.
33. Seo JH, Sung HJ, Park KH et al. Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-contaming adjuvant therapy. Invest New Drugs 2009; 27 (1): 67–73.
34. O’Shaughnessy J, Miles D et al. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. JCO 2002; 12: 2812–23.
35. Slamon D, Leyland-Jones B, Shak S et al. Use of Chemotherapy plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 2001; 344, 11: 783–92.
36. Twelves C, Trigo JM, Jones R et al. Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study. Eur J Cancer 2008; 44 (3): 419–26.
37. Venturini M, Durando A, Garrone O et al. Capecitabine in Combination with Docetaxel and Epirubicin in Patients with Previously Untreated, Advanced Breast Carcinoma. Cancer 2003; 97, 5: 1174–80.
38. Zhou NN, Lin XB, Liu DG et al. Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer. Ai Zheng 2008; 27 (9): 947–50.

И.В.Колядина, Н.П.Макаренко, И.В.Поддубная

Кафедра онкологии ГОУ ДПО РМАПО Росздрава, Москва